CHRS Coherus Oncology, Inc. — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$1.45

Period return

+0.17 (+13.28%)

Volume

908.2K

2026-06-05O $1.57 H $1.57 L $1.44 C $1.45MA5 $1.52MA20 $1.61MA60 $1.69MA120 $1.7

6M · 124 barsYahoo Finance · USD2025-12-08 → 2026-06-05

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 05. 12.MediumBUY26 days ago
Guggenheim: Buy
US analyst rating / recommendation change.
2026. 01. 22.MediumBUY5 months ago
Oppenheimer: Outperform
US analyst rating / recommendation change.
2025. 09. 04.MediumBUY9 months ago
Maxim Group: Buy
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $7.8 · 5 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27. It also develops CHS-114, an investigational human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME) patients with head and neck squamous cell carcinoma. It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreements with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as Coherus BioSciences, Inc. and changed its name to Coherus Oncology, Inc. in May 2025. The company was incorporated in 2010 and is based in Redwood City, California.

Sector: Healthcare
Industry: Biotechnology
HQ: Redwood City, CA, United States

2025. 04. 29.LowBUYlast year

HC Wainwright & Co.: Buy